第１个血管紧张素Ⅱ受体拮抗剂氯沙坦于１９９４年在国外上市，１９９８年在我国上市，给降压治疗带来更多的选择。从其作用机制来看，它可避免ＡＣＥＩ（血管紧张素转化酶抑制剂）的某些不良反应，因不直接影响缓激肽的降解，使咳嗽发生率降低。但由于本品在国内应用时间... The first angiotensin Ⅱ receptor antagonist losartan was listed abroad in 1994, and was listed in China in 1998, bringing more choices for antihypertensive treatment. From its mechanism of action, it can avoid some of the adverse effects of ACEI (angiotensin converting enzyme inhibitor), which does not directly affect the degradation of bradykinin, reducing the incidence of cough. However, due to the product in the domestic application of time ...